论文部分内容阅读
一越南药企状告中国食药监总局一案最终逆袭收场,原告获胜。这是对中国密闭化药审程序的鞭挞,也是对自由裁量权的制衡。每年有近三成药品申请在审批环节被“枪毙”。以2014年为例,审结的化学药品、中药、生物制剂约1900个受理号,约有560个不被批准,最终等到被“枪毙”的结果要经过几年的时间。在每年几百个被“枪毙”的申请企业中,越南一家名为VELLPHARM的药厂(以下简称越南药厂)自2011年开始与中国食品药品监督管理总局(以下简称
A Vietnamese drug company sued China Food and Drug Administration final counterattack ended, the plaintiff won. This is a whipping on China’s closed procedure of drug examination, as well as a check and balance on discretion. Nearly 30% of the applications for drugs are “shot dead” at the examination and approval session each year. Taking 2014 as an example, about 1,900 acceptance numbers of chemical drugs, traditional Chinese medicines and biological agents concluded, and about 560 are not approved. Eventually, it will take several years for the results of the “shoot-out”. Among the hundreds of applicants that have been “shot dead” each year, a pharmaceutical company in Vietnam called VELLPHARM (hereinafter referred to as “Vietnam Pharmaceutical Factory”) started to cooperate with China Food and Drug Administration (hereinafter referred to as "